The Eir Ventures Team
The team is highly experienced with documented successes in
Life science venture capital · Global pharma industry
Medical scientific research · Product development and launches
Hands-on management of venture backed companies
Private and public market transactions as well as M&A
We have complementary backgrounds in relevant fields, and have worked together during many years in different capacities
Magnus Persson, MD, PhD, Associate Professor
Magnus is a Physician and Scientist, who early in his career successfully started a medical technology company (Aerocrine) and sold it, joined Sanofi and subsequently has been a Partner at two life science Venture Capital firms, HealthCap in Stockholm and The Column Group in San Francisco. He has had a role in dozens of investments and exits. Lately he has been an independent Chairman/Board member in several private and public companies in the Nordics, as well as in the US, and worked on a weekly basis as a clinician. Magnus has been actively involved in a number of successful pharma spin-outs. He has experience from the academic incubator space as CEO at Karolinska Institutet Holding.
Amanda Hayward, PhD
Amanda is a Molecular Biologist and has spent nearly 20 years on the business side with a focus on company building, venture investment, executive leadership, finance and business development. Amanda has been a co-founder of and operator within several academic and pharma-sourced spin-outs, and for a number of the spin-outs has taken interim executive management roles. Amanda’s venture experience comes from being a partner-level member of two US based venture funds, with an international investment scope, Baxalta Ventures and Connecticut Innovations. Amanda has Board level and operational experience in the US and Europe, including in the Nordics.
Stephan Christgau, PhD
Stephan has a PhD in Protein Chemistry and immunology from UCSF. Stephan has broad executive experience from private as well as public biotech companies with responsibilities for R&D, operations, clinical development and corporate strategy. Stephan was a founding member of the corporate life science venture capital group Novo Seeds and for more than 12 years has worked in life science venture capital as an active company creator and early investor. His investments have mainly focused on the Nordic area, where Stephan has led the creation and funding of more than 20 companies.
Andreas Segerros, MSc, MBA
Andreas is a MSc in Biochemistry and an MBA in International Financing. He has spent most of his career in global pharma, with executive positions (R&D, Marketing and Corporate Development) in the US, Europe and Japan with Pharmacia and Ferring Pharmaceuticals. He has been a Partner at Sunstone Capital where he was responsible for a number of industry spin-outs and US IPO. Andreas has made numerous investments in successful companies and has Board level and CEO experience from the US and Europe, which also have included eHealth and industrial biotech.
Alexander Mata, PhD, MBA
Alexander has a PhD is cell and molecular biology and an MBA in Management. He started off his corporate life science career in the global pharma industry at Novartis and Bayer, where he held a number of strategic R&D position. His most recent assignment was as healthcare Equity Analyst at Alecta, which has given him institutional experience in identifying and evaluating larger life science investments.